<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of the present study was to determine after what time period <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi> formation contributes most to ischemic brain damage in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, using a <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi> scavenger, EPC-K1, <z:chebi fb="0" ids="29073">L-ascorbic acid</z:chebi> 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-<z:chebi fb="0" ids="32908">tridecyl</z:chebi>)-2H-1-be nzopyran-6yl-hydrogen phosphate] <z:chebi fb="0" ids="26218">potassium salt</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was produced by thrombotic occlusion of the left middle cerebral artery in rats </plain></SENT>
<SENT sid="2" pm="."><plain>After evaluation of the pharmacokinetics of EPC-K in the brain tissue and plasma following 10 mg/kg intravenous bolus treatment of conscious rats, we investigated the neuroprotective effect of EPC-K1 in the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model </plain></SENT>
<SENT sid="3" pm="."><plain>A single intravenous bolus of EPC-K1 was given immediately, 3 or 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and cerebral brain damage was measured 24 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>When EPC-K1 was injected 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, a significant (P &lt; 0.01) reduction of cerebral brain damage was observed </plain></SENT>
<SENT sid="5" pm="."><plain>EPC-K1 delivered by intravenous infusion that started immediately after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and lasted for 24 h, also significantly (P &lt; 0.05) reduced brain damage, but the efficacy of the neuroprotective effect was the same as that of the 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> bolus treatment </plain></SENT>
<SENT sid="6" pm="."><plain>These results may indicate that the period of <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi> formation most critical for ischemic brain damage is a few hours after the third hour following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in this model </plain></SENT>
</text></document>